NDLI: Evolution of capecitabine dosing in breast cancer.

Please wait, while we are loading the content...

Year: 2016 Volume: 16

Year: 2015 Volume: 15

Year: 2014 Volume: 14

Year: 2013 Volume: 13

Year: 2012 Volume: 12

Year: 2011 Volume: 11

Year: 2010 Volume: 10

Year: 2010 Volume: 10 Issue: 6

Year: 2010 Volume: 10 Issue: 5

Year: 2010 Volume: 10 Issue: 4

Year: 2010 Volume: 10 Issue: 3

Year: 2010 Volume: 10 Issue: Supplementary 3

Year: 2010 Volume: 10 Issue: 2

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.

Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging.

Breast cancer hormone receptor assay results of core needle biopsy and modified radical mastectomy specimens from the same patients.

A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.

Rheumatic disorders and functional disability with aromatase inhibitor therapy.

Evolution of capecitabine dosing in breast cancer.

Does tumor size trump biology?

Integrating bevacizumab into the treatment of patients with early-stage breast cancer: focus on cardiac safety.

Oncologists' recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status.

Year: 2010 Volume: 10 Issue: Supplementary 2

Year: 2010 Volume: 10 Issue: 1

Year: 2010 Volume: 10 Issue: Supplementary 1

Year: 2009 Volume: 9

Year: 2008 Volume: 8

Year: 2007 Volume: 7

Evolution of capecitabine dosing in breast cancer.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Naughton, Michael
Description	Country affiliation: United States Author Affiliation: Naughton M ( Washington University School of Medicine, St. Louis, MO 63141, USA. mnaughto@dom.wustl.edu)
Abstract	In the United States, poor patient tolerability of the standard capecitabine dosing regimen (1250 mg/m2 twice daily on days 1-14 administered every 21 days) limits the established benefit of the agent. The observation that patient tolerability improves and efficacy is maintained with lower doses led to the investigation of various doses and schedules in patients with metastatic breast cancer. Capecitabine monotherapy in daily doses of 1000-2560 mg/m2 or in combination with a taxane in daily doses of 825-1250 mg/m2 has confirmed that tolerability improves and efficacy is maintained with lower-than-standard doses. Similar results have been observed with various dosing schedules, including continuous administration and 28-day, 7-day, and 7-days-on/7-days-off cycles. These findings suggest that capecitabine administered in a variety of doses and schedules might be a viable alternative to anthracycline-containing regimens as first- or second-line treatment in patients with metastatic breast cancer.
File Format	HTM / HTML
ISSN	15268209
Issue Number	2
Volume Number	10
e-ISSN	19380666
Journal	Clinical Breast Cancer
Language	English
Publisher	Elsevier
Publisher Date	2010-04-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Oncology Antimetabolites, Antineoplastic Administration & Dosage Breast Neoplasms Drug Therapy Deoxycytidine Analogs & Derivatives Fluorouracil Capecitabine Clinical Trials As Topic Drug Administration Schedule Female Humans Journal Article Research Support, Non-u.s. Gov't Review
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in